Core A: While pluripotent stem cells and their differentiated progeny have tremendous promise for cardiac repair, their routine culture is demanding and requires considerable expertise and continuous attention to quality control. Based on our extensive prior experience with these cells, we have found that centralization of cell culture efforts is the best way to ensure consistency and efficiency in the large-scale production of undifferentiated and differentiated cells. Hence, the primary goal ofthe Stem Cell Core will be to generate large numbers of undifferentiated embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs) and cardiac derivatives for distribution to the individual projects in this program. The Core will also work closely with investigators in Project 2 to optimize the derivation of cardiomyocytes from canine ESCs. Finally, the Core will also develop and share optimized protocols for the genetic modification of ESCs and iPSCs, including the generation of cell type specific reporter lines via transgenesis in bacterial artficial chromosomes (BACs). In sum, the Core will undertake three specific aims: 1) to provide the individual projects with the stem cells and cardiac derivatives needed to complete their respective aims, 2) to develop BAC transgenesis and optimize the delivery of modified BACs into human ESCs and iPSCs), and 3) to provide training and technical assistance with in vitro experiments involving pluripotent stem cells or their differentiated progeny.
The goal of this program is to develop stem cell based therapies for myocardial infarction, the number one cause of death in the U.S. However, the culture of stem cells is technically challenging, and so we need a centralized Stem Cell Core for the scaled production of stem cells and stem cell-derived heart muscle cells.
|Lundy, Scott D; Gantz, Jay A; Pagan, Chelsea M et al. (2014) Pluripotent stem cell derived cardiomyocytes for cardiac repair. Curr Treat Options Cardiovasc Med 16:319|
|Jiao, Alex; Trosper, Nicole E; Yang, Hee Seok et al. (2014) Thermoresponsive nanofabricated substratum for the engineering of three-dimensional tissues with layer-by-layer architectural control. ACS Nano 8:4430-9|
|Chong, James J H; Murry, Charles E (2014) Cardiac regeneration using pluripotent stem cells--progression to large animal models. Stem Cell Res 13:654-65|
|Coulombe, Kareen L K; Bajpai, Vivek K; Andreadis, Stelios T et al. (2014) Heart regeneration with engineered myocardial tissue. Annu Rev Biomed Eng 16:1-28|
|Lundy, Scott D; Murphy, Sean A; Dupras, Sarah K et al. (2014) Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J Mol Cell Cardiol 72:350-9|
|Hartman, Matthew E; Liu, Yonggang; Zhu, Wei-Zhong et al. (2014) Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias. FASEB J 28:3007-15|
|Yang, Xiulan; Pabon, Lil; Murry, Charles E (2014) Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 114:511-23|
|Thomson, Kassandra S; Dupras, Sarah K; Murry, Charles E et al. (2014) Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses. Angiogenesis 17:195-205|
|Shiba, Yuji; Filice, Dominic; Fernandes, Sarah et al. (2014) Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model. J Cardiovasc Pharmacol Ther 19:368-381|
|Bahrami, Arya J; Gunaje, Jagadambika J; Hayes, Brian J et al. (2014) Regulator of G-protein signaling-5 is a marker of hepatic stellate cells and expression mediates response to liver injury. PLoS One 9:e108505|
Showing the most recent 10 out of 44 publications